LOTTE BIOLOGICS Signs CDMO Deal with Ottimo Pharma for Cancer Antibody

• LOTTE BIOLOGICS has signed a contract manufacturing agreement with Ottimo Pharma to produce antibody drug substance for Jankistomig.

• The manufacturing will take place at the Syracuse Bio Campus in New York, reinforcing LOTTE BIOLOGICS’ presence in the global CDMO market.

LOTTE BIOLOGICS announced on 19 June 2025 that it has entered into a contract manufacturing agreement with Ottimo Pharma to produce an antibody therapeutic drug substance. The agreement was signed at BIO INTERNATIONAL 2025, held at the Boston Convention and Exhibition Center.

Under the agreement, LOTTE BIOLOGICS will manufacture Ottimo Pharma’s PD1/VEGFR2 dual pathway antibody, Jankistomig, at its Syracuse Bio Campus in New York. The deal supports Ottimo’s preparations for IND submission and clinical trial initiation.

“This agreement serves as further validation of our competitiveness as a CDMO in the global antibody therapeutics market,” said James Park, CEO of LOTTE BIOLOGICS. “We will continue striving not only to supply high-quality medicines that meet global standards, but also to become a company that delivers greater value to both our partners and patients.”

Ottimo Pharma’s Vice President of Technical Development & Manufacturing, Joseph Shultz, commented: “This manufacturing collaboration marks a significant milestone in our commitment to advancing Jankistomig with speed and precision. Partnering with Lotte’s proven biomanufacturing capabilities enhances our operational readiness.”

LOTTE BIOLOGICS provides CDMO services across the full development lifecycle, from cell line development to large-scale manufacturing. In addition to its operational site in New York, the company plans to open Plant 1 at its Songdo Bio Campus in 2027, with a projected 120,000-litre capacity. The company is also expanding collaborations across Asia and Europe to offer integrated, end-to-end contract manufacturing solutions.